Scarica l'app Stockscreener
1.35
4.23%
0.05
Precedente Chiudi:
$1.30
Aprire:
$1.3179
Volume 24 ore:
63,678
Relative Volume:
0.48
Capitalizzazione di mercato:
$20.71M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.2018
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
+12.92%
1M Prestazione:
+1.12%
6M Prestazione:
-22.57%
1 anno Prestazione:
-19.35%
Intervallo 1D:
$1.295
$1.40
Intervallo di 1 settimana:
$1.15
$1.40
Portata 52W:
$1.14
$6.40
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Confronta LGVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.35 | 20.71M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.24 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
528.53 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.07 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.05 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener
Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times
Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq
Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan
18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World
Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks
Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance
Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World
Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq
Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance
Is Palantir Stock a Buy at All-Time Highs? - The Globe and Mail
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire
Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq
Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India
Longeveron Reports Q1 2025 Progress and Financials - TipRanks
Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada
Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan
Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times
Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire
FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha
Where Will Palantir Stock Be in 1 Year? - The Globe and Mail
Longeveron Files $70 Million Mixed Shelf - MarketScreener
Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener
Stem Cell Treatment Improves Alzheimer's Symptoms - Newsmax
Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World
Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals
FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa
FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com
Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView
FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Longeveron's Cell Therapy Lomecel-B Improves Cognitive Function in Mild Alzheimer Disease - CGTLive®
Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com
Laromestrocel shows promise in Alzheimer’s trial - Investing.com India
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times
Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks
Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Longeveron Inc Azioni (LGVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):